Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.) Patents (Class 424/139.1)
  • Semaphorin 3C (Sema3C) Inhibitor Therapeutics, Methods, and Uses
    Publication number: 20150010561
    Abstract: Provided are methods, uses and pharmaceutical compositions for treatment of prostate cancer with a SEMA3C inhibitor in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The prostate cancer may be an androgen receptor (AR) positive prostate cancer and the SEMA3C inhibitor may be selected from one or more of the following: an antibody, a SEMA3C peptide, an antisense RNA, a siRNA, a shRNA or a small molecule.
    Type: Application
    Filed: July 9, 2014
    Publication date: January 8, 2015
    Inventors: Christopher J. Ong, Martin E. Gleave, Norihiro Hayashi, James Peacock
  • Methods of Identifying a Compound that Increases or Decreases the Interaction of Hn-33 with Synaptotagmin II
    Publication number: 20150010535
    Abstract: This application is based, inter alia, on the discovery of a binding interaction between the Hn-33 hemagglutinin polypeptide of the type A Clostridium botulinum neurotoxin complex and synaptosomal proteins, including synaptotagmin II (Syt II). Methods of screening for compounds that modulate, e.g., increase or decrease, this interaction are provided. Also provided are compositions and methods for targeting compounds to neuronal and cancer cells by coupling the compounds to Hn-33 or biologically active Hn-33 variants.
    Type: Application
    Filed: May 19, 2014
    Publication date: January 8, 2015
    Inventor: Bal Ram Singh
  • PULMONARY HYPERTENSION
    Publication number: 20150010562
    Abstract: The disclosure relates to agents that inhibit the activity of Tumour Necrosis Factor Apoptosis-Inducing Ligand [TRAIL] and their use in the treatment of pulmonary hypertension.
    Type: Application
    Filed: October 23, 2012
    Publication date: January 8, 2015
    Applicant: PH Therapeutics
    Inventor: Allan Lawrie
  • RSPO BINDING AGENTS AND USES THEREOF
    Publication number: 20150010571
    Abstract: The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate ?-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: June 27, 2014
    Publication date: January 8, 2015
    Inventors: Austin L. GURNEY, Fumiko Takada Axelrod, Timothy Charles Hoey, Cecile Chartier-Courtaud
  • METHODS AND COMPOSITIONS FOR USING MHC CLASS II INVARIANT CHAIN POLYPEPTIDES AS A RECEPTOR FOR MACROPHAGE MIGRATION INHIBITORY FACTOR
    Publication number: 20150010570
    Abstract: Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer.
    Type: Application
    Filed: June 4, 2014
    Publication date: January 8, 2015
    Inventors: Richard J. Bucala, Lin Leng, Christine N. Metz
  • Methods for Treating Corneal and Conjunctival Inflammation and Inflammatory Disorders
    Publication number: 20150010563
    Abstract: Provided herein are methods for reducing corneal inflammation, reducing inflammatory cell (e.g., dendritic cell) recruitment to the cornea, and treating an corneal inflammatory disorder in a subject that include administering to the subject one or more of a MadC AM-1 antagonist, an ?4?7 integrin antagonist, a L-selectin antagonist, and an E-selectin antagonist. Also provided are compositions containing one or more of a MadC AM-1 antagonist, an ?4?7 integrin antagonist, a L-selectin antagonist, and an E-selectin antagonist, and kits containing these compositions.
    Type: Application
    Filed: February 21, 2013
    Publication date: January 8, 2015
    Applicant: Massachusetts Eye & Ear Infirmary
    Inventors: Pedram Hamrah, Ulrich von Andrian, Aslihan Turhan
  • ANTI-TLR4 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20150010559
    Abstract: This invention relates generally to antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and to methods of using the anti-TLR4 antibodies in methods of preventing transplant rejection and/or prolonging survival of transplanted biological material.
    Type: Application
    Filed: May 15, 2014
    Publication date: January 8, 2015
    Applicant: NovImmune S.A.
    Inventors: Marie Kosco-Vilbois, Katrien L. De Graaf, Thierry Berney, Santa Giovannoni, Domenic Bosco
  • Inhibitors Of Complement Activation
    Publication number: 20150010569
    Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.
    Type: Application
    Filed: May 29, 2014
    Publication date: January 8, 2015
    Inventors: Michael Fung, William N.C. Sun, Cecily R. Y. Sun
  • OPTIMIZED Fc VARIANTS
    Publication number: 20150010550
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: August 12, 2014
    Publication date: January 8, 2015
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • ANG-2 SPECIFIC ANTIBODIES AND USES THEREOF
    Publication number: 20150010572
    Abstract: Provided are an anti-Ang-2 antibody or antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang-2), related compositions and pharmaceutical compositions, and methods for using such compositions and pharmaceutical compositions.
    Type: Application
    Filed: July 2, 2014
    Publication date: January 8, 2015
    Inventors: Yoon Sook LEE, Chung Ho Kim, Kyung Eun Kim, Hyung-Chan Kim, Kwang Hoon Lee, Hyo Seon Lee, Sang Yeul Han
  • HUMAN PAC1 ANTIBODIES
    Publication number: 20150010560
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.
    Type: Application
    Filed: June 13, 2014
    Publication date: January 8, 2015
    Inventors: Cen XU, Agnes Eva HAMBURGER
  • COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND FIBROSIS
    Publication number: 20150010552
    Abstract: The present invention features compositions featuring agents that bind to denatured collagen and methods of using such agents to treat or prevent fibrosis or inflammation in a subject.
    Type: Application
    Filed: September 17, 2014
    Publication date: January 8, 2015
    Inventors: Peter C. Brooks, Leif Oxburgh, Jennifer M. Caron
  • Methods of treating a tauopathy
    Patent number: 8926974
    Abstract: The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: January 6, 2015
    Assignee: iPierian, Inc.
    Inventors: Irene Griswold-Prenner, Nancy E. Stagliano, Vu Dang, Sami Hussain, Jessica Michelle Bright
  • Anti-CD38 antibodies
    Patent number: 8926969
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: January 6, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shewta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • OSTEOPONTIN ISOFORM A INHIBITORS AND METHODS OF USE
    Publication number: 20150004157
    Abstract: The present invention relates to a therapeutic comprising an osteopontin isoform a (“OPNa”) inhibitor where the OPNa inhibitor blocks activity of extracellular OPNa exon 4. The OPNa inhibitor is selected from the group consisting of (i) an exon-4 specific antibody or binding portion thereof; (ii) a peptide mimic of OPNa exon 4 or a fragment thereof; (iii) a nucleic acid aptamer that specifically binds to OPNa exon 4 or a fragment thereof; and (iv) a peptide inhibitor that binds to OPNa exon 4 or a fragment thereof. The present invention also relates to methods of inhibiting tumor growth and/or metastasis in a subject, treating a subject with chemotherapeutic resistance, and methods of increasing tumor cell sensitivity to a cancer therapeutic by administering an OPNa inhibitor according to the present invention.
    Type: Application
    Filed: February 13, 2013
    Publication date: January 1, 2015
    Applicant: NEW YORK UNIVERSITY
    Inventors: Harvey I. Pass, Jessica S. Donington, Chandra M. Goparaju
  • RSV G PROTEIN SPECIFIC ANTIBODIES
    Publication number: 20150004155
    Abstract: The disclosure relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The disclosure further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for, at least in part, treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.
    Type: Application
    Filed: November 16, 2012
    Publication date: January 1, 2015
    Applicant: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Etsuko Yasuda
  • HYPOXIA-INDUCED MITOGENIC FACTOR
    Publication number: 20150004172
    Abstract: We found that FIZZ1/RELM? is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELM? was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELM? protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.
    Type: Application
    Filed: September 10, 2014
    Publication date: January 1, 2015
    Inventors: Roger Johns, Xingwu Teng, Dechun Li
  • COMPOSITIONS AND METHODS FOR ANALYZING HISTIDINE PHOSPHORYLATION
    Publication number: 20150004173
    Abstract: A peptide is disclosed of the general structure: Z—W—Y, wherein Z and Y are independently a one to eight amino acid sequence wherein the amino acids are selected from glycine and alanine and W is a non-hydrolyzable pHis analogue. Such peptides can be used to produce sequence-independent anti-phosphohistidine antibodies. Also provided are antibodies that specifically bind to a peptide comprising a phosphohistidine (or a non-hydrolyzable pHis analogue) but fail to specifically bind to an identical peptide containing histidine instead of phosphohistidine.
    Type: Application
    Filed: September 12, 2014
    Publication date: January 1, 2015
    Inventors: Magda Stankova, Fahad Al-Obeidi, Jacques Mauger, Robert A. Binnie, Tony Hunter, Jill Meisenhelder, Stephen Rush Fuhs
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20150004168
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: June 18, 2014
    Publication date: January 1, 2015
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Kurt Alex HELDWEIN, Igor SPLAWSKI, Jennifer BROGDON, Joshua GOLDSTEIN, William DOLE, John TRAUGER, Chonghui ZHANG
  • Methods of Treating Brain Injury
    Publication number: 20150004169
    Abstract: Embodiments of the invention are directed to compositions and methods related to Tau oligomers and Tau oligomer specific antibodies and their use in detecting and/or treating traumatic brain injury or chronic traumatic encephaly.
    Type: Application
    Filed: July 7, 2014
    Publication date: January 1, 2015
    Applicant: The Board of Regents of the University of Texas System
    Inventor: Rakez Kayed
  • Angiogenic and Immunologic Applications of Anti-CD160 Specific Compounds Obtainable From mAb CL1-R2
    Publication number: 20150004170
    Abstract: The present invention relates to biological and medical applications of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD160 compounds in the fields of EC angiogenesis, and NK and T cytokine production.
    Type: Application
    Filed: July 8, 2014
    Publication date: January 1, 2015
    Inventors: Armand Bensussan, Laurence Boumsell, Philippe Le Bouteiller
  • PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER
    Publication number: 20150004171
    Abstract: This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof in a therapeutic and/or preventive agent for cancers. Specifically, this invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancers, comprising the antibody or fragment thereof as an active ingredient.
    Type: Application
    Filed: February 21, 2013
    Publication date: January 1, 2015
    Applicant: TORAY INDUSTRIES, INC.
    Inventors: Shinichi Kobayashi, Fumiyoshi Okano, Takanori Saito
  • SECRETED PROTEINS
    Publication number: 20150004165
    Abstract: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.
    Type: Application
    Filed: September 8, 2014
    Publication date: January 1, 2015
    Applicant: INCYTE CORPORATION
    Inventors: Henry Yue, Monique G. Yao, Ameena R. Gandhi, Mariah R. Baughn, Anita Swarnakar, Narinder Walia, Madhusudan M. Sanjanwala, Michael Thorton, Vicki S. Kaulback, Yan Lu, Kimberly J. Gietzen, Neil Burford, Li Ding, April J.A. Hafalia, Y. Tom Tang, Olga Bandman, Bridget A. Warren, Cynthia D. Honchell, Dyung Aina M. Lu, Kavitha Thangaveln, Sally Lee, Yuming Xu, Junming Yang, Preeti G. Lal, Bao M. Tran, Craig H. Ison, Brendan M. Duggan, Stephanie Kareht
  • Use Of Antibody
    Publication number: 20150004164
    Abstract: The present invention provides a specific binding molecule that binds to Annexin-1 (Anx-A1) for use in the treatment of obsessive compulsive disorder (OCD) or a disease related to OCD. The invention also provides a pharmaceutical composition comprising a specific binding molecule of the invention for use in the treatment of obsessive compulsive disorder (OCD) or a disease related to OCD.
    Type: Application
    Filed: December 14, 2012
    Publication date: January 1, 2015
    Inventors: Fulvio D'Acquisto, Mauro Perretti
  • Humanized anti-beta-amyloid antibodies
    Patent number: 8921523
    Abstract: Antigen binding proteins that bind ?-amyloid peptide, in particular human ?-amyloid peptide; methods of treating diseases or disorders characterized by elevated ?-amyloid levels or ?-amyloid deposits, particularly Alzheimer's disease and diseases or disorders affecting the eye or optic nerve characterized by elevated ?-amyloid levels or ?-amyloid deposits, including age related macular degeneration and glaucoma type diseases and ?-amyloid dependent cataract formation, with the antigen binding proteins; pharmaceutical compositions comprising the antigen binding proteins; and methods of manufacture.
    Type: Grant
    Filed: December 9, 2008
    Date of Patent: December 30, 2014
    Assignee: Glaxo Group Limited
    Inventors: Philippe Marc Louis Alard, Ian Richard Catchpole, Jonathan Henry Ellis, Susannah Karen Ford, Volker Germaschewski, Gerald Wayne Gough, Alan Peter Lewis, Peter Ernest Soden, Pamela Joan Thomas, Trevor Anthony Kenneth Wattam
  • Stable liquid VEGF antagonist formulations
    Patent number: 8921316
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: December 30, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel Dix, Kelly Frye, Susan Kautz
  • Myostatin binding agents, nucleic acids encoding the same, and methods of treatment
    Patent number: 8920798
    Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: December 30, 2014
    Assignee: Amgen Inc.
    Inventors: Huiquan Han, Hosung Min, Thomas Charles Boone
  • Compositions and methods for the detection diagnosis and therapy of hematological malignancies
    Patent number: 8920776
    Abstract: Disclosed are methods and compositions for the detection, diagnosis, prognosis, and therapy of hematological malignancies, and in particular, B cell leukemias, lymphomas and multiple myelomas. Disclosed are compositions, methods and kits for eliciting immune and T cell responses to specific malignancy-related antigenic polypeptides and antigenic polypeptide fragments thereof in an animal. Also disclosed are compositions and methods for use in the identification of cells and biological samples containing one or more hematological malignancy-related compositions, and methods for the detection and diagnosis of such diseases and affected cell types. Also disclosed are diagnostic and therapeutic kits, as well as methods for the diagnosis, therapy and/or prevention of variety of leukemias and lymphomas.
    Type: Grant
    Filed: January 22, 2003
    Date of Patent: December 30, 2014
    Assignee: Corixa Corporation
    Inventors: Alexander Gaiger, Paul A. Algate, Jane Mannion, Jonathan David Clapper, Aijun Wang, Nadia Ordonez, Lauren Carter, Patricia Dianne McNeill
  • NATURALLY OCCURRING AUTOANTIBODIES AGAINST ALPHA-SYNUCLEIN THAT INHIBIT THE AGGREGATION AND CYTOTOXICITY OF ALPHA-SYNUCLEIN
    Publication number: 20140377271
    Abstract: The present invention refers to human antibodies which are directed against ?-Synuclein (?-Syn) and their use in medicine and diagnosis.
    Type: Application
    Filed: April 18, 2014
    Publication date: December 25, 2014
    Applicant: Dr. Rentschler Holding GmbH & Co. KG
    Inventors: Richard DODEL, Michael BACHER, Daniela BESONG AGBO, Sascha HAGEMANN, Monika BALZER-GELDSETZER, Bernd REHBERGER, Renee WEBER
  • ANTI-HER3 ANTIBODIES AND USES THEREOF
    Publication number: 20140377273
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • Methods and Compositions Involving NKG2D Inhibitors and Cancer
    Publication number: 20140377266
    Abstract: Embodiments methods and compositions involving inhibitors of the immunoreceptor Natural Killer Group 2, Member D, (NKG2D) for inhibiting tumor progression and treating cancer.
    Type: Application
    Filed: September 7, 2012
    Publication date: December 25, 2014
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Thomas Spies, Veronika Spies
  • CLEAVAGE INHIBITORS OF TRANSFORMING GROWTH FACTOR BETA TYPE I RECEPTOR AND USES THEREOF IN CANCER THERAPY
    Publication number: 20140377268
    Abstract: Disclosed herein are methods to inhibit cleavage of a type I receptor of transforming growth factor beta (T?RI) and reduce cancer cell invasiveness/metastasis, and agents and pharmaceutical compositions for use in these methods. Also disclosed herein are methods for identifying agents that inhibit cleavage of T?RI and methods for diagnosing and/or prognosing cancer based on nuclear localization of a intracellular domain of T?RI, which is a product of T?RI cleavage.
    Type: Application
    Filed: March 13, 2012
    Publication date: December 25, 2014
    Applicant: Ludwig Institute for Cancer Research Ltd.
    Inventors: Marene Inga-Britt Landstrom, Yabing Mu, Reshma Sundar, Noopur Thakur, Shyam Kumar Gudey, Maria Ekman, Carl-Henrik Heldin
  • Novel Antibody Recognizing a Small Subset of Human Hematopoietic Cells
    Publication number: 20140377172
    Abstract: The subject invention pertains to antibodies that have binding specificity for an antigen that is expressed on a subset of human, hematopoietic mononuclear cells, including a hematopoietic stem cell population, but is not expressed on normal, mature myeloid cells. In one embodiment, a monoclonal antibody, MG1, is provided. This antibody is useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marrow transplantation, genetic therapy, and in treating other diseases of the hematopoietic system. Cell suspensions containing MG1+ human hematopoietic cells are also provided, as well as therapeutic methods employing the cell suspensions. The subject invention also pertains to the novel antigen recognized by the subject antibodies.
    Type: Application
    Filed: March 4, 2010
    Publication date: December 25, 2014
    Applicant: Morphogenesis, Inc.
    Inventors: Michael J.P. Lawman, Patricia Lawman
  • ANTI-HER3 ANTIBODIES AND USES THEREOF
    Publication number: 20140377272
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • S100A4 antibodies and therapeutic uses thereof
    Patent number: 8916152
    Abstract: The invention relates to antibodies against S100A4, methods for the preparation of these antibodies, pharmaceutical compositions comprising these antibodies, and therapeutic and diagnostic uses thereof.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: December 23, 2014
    Assignee: Lykera Biomed SA
    Inventors: Jose Luis Hernandez Miguez, Jaume Adan Plana, Josep Maria Martinez Escola, Marc Masa Alvarez, Ramon Messeguer Peypoch, Francesc Mitjans Prat, Sheila Dakhel Plaza, Antonio Coll Manzano, Rosa Ma Hervas Villegas, Carme Calvis Calpe, Laura Padilla Garcia, Lourdes Tatiana Roque Navarro, Laura Barbera Ferrando, Manuel Rivas Canas, Luis Angel Gomez Casajus
  • Methods of Treating Pain by Inhibition of VGF Activity
    Publication number: 20140370024
    Abstract: The present disclosure relates to a method of treating pain, in particular neuropathic pain, comprising administering a therapeutically effective amount of an inhibitor of VGF activity resulting from binding of VGF or a peptide of the type TLQP-21 to the receptor qC1qR. The disclosure also relates to and methods of screening for said inhibitors.
    Type: Application
    Filed: January 25, 2013
    Publication date: December 18, 2014
    Applicant: Imperial Innovations, Ltd.
    Inventors: Kenji Okuse, Alessandro Pristera
  • ERG MONOCLONAL ANTIBODIES
    Publication number: 20140370023
    Abstract: Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In other embodiments, the monoclonal antibodies are chimeric, having the light and heavy chain variable regions of a non-human ERG antibody. Methods of using the antibodies to detect ERG, or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript, are also provided, including methods of detecting ERG or ERG fusion events in a clinical setting.
    Type: Application
    Filed: May 27, 2014
    Publication date: December 18, 2014
    Inventors: Shiv Srivastava, Shyh-Han Tan, Albert Dobi
  • METHODS FOR THE TREATMENT OF GOUT
    Publication number: 20140370002
    Abstract: Disclosed are methods for the treatment and/or prevention of gout, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.
    Type: Application
    Filed: December 20, 2013
    Publication date: December 18, 2014
    Applicant: XOMA (US) LLC
    Inventor: Alan M. Solinger
  • Cytomegalovirus Surface Protein Complex For Use in Vaccines and as a Drug Target
    Publication number: 20140370026
    Abstract: Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pULl28or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.
    Type: Application
    Filed: September 2, 2014
    Publication date: December 18, 2014
    Inventors: THOMAS SHENK, DAI WANG
  • Anti-Alpha Synuclein Binding Molecules
    Publication number: 20140369940
    Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: June 22, 2012
    Publication date: December 18, 2014
    Applicants: University of Zurich, Biogen IDEC International Neuroscience GmbH
    Inventors: Andreas Weihofen, Jan Grimm, Cristoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
  • USES OF MAMMALIAN CYTOKINES AND AGONISTS; RELATED REAGENTS
    Publication number: 20140370025
    Abstract: Provided are methods of treatment for tumors. In particular, provided are methods of using of a cytokine molecule and its receptor.
    Type: Application
    Filed: August 29, 2014
    Publication date: December 18, 2014
    Inventor: Martin Oft
  • Pharmaceutical composition for treating and/or preventing cancer
    Patent number: 8911740
    Abstract: According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody or a fragment thereof as an active ingredient having immunological reactivity with a partial polypeptide of CAPRIN-1, which is represented by any of even-numbered sequences of SEQ ID NOS: 2 to 30, wherein the polypeptide has the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 37.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: December 16, 2014
    Assignee: Toray Industries, Inc.
    Inventors: Takanori Saito, Fumiyoshi Okano, Shinichi Kobayashi
  • Monoclonal antibodies specific for beta-amyloid x-37 and uses thereof
    Patent number: 8911731
    Abstract: The present invention provides monoclonal antibodies which specifically recognize the shorter A? peptides obtained after cleavage of the APP protein mediated by ?-secretase, i.e. the A?-peptide fragments A?1-37, A?3-37, A?3p-37, A?1-37 and A?11p-37, and other like fragments ending at the 37th amino acid of APP, hereinafter also referred to as the A?x-37 peptides. It further provides hybridoma cells producing the monoclonal antibodies as well as methods for producing the antibodies and the hybridoma cells; and an immunoassay for an A?x-37 peptide by a competitive method or a sandwich method using the antibody of the present invention; and methods for measuring the level of A?x-37 peptides in a sample, such as a biological sample.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: December 16, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Marc Hubert Mercken, Marianne Borgers, Marc Maria Pierre Pelagie Vandermeeren, Bianca Julia J Van Broeck
  • Methods of using antibodies to block human thymic stromal lymphopoietin (TSLP) receptor activity
    Patent number: 8911730
    Abstract: The present invention provides Thymic Stromal Lymphopoietin Receptor (TSLPR) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TSLPR polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TSLPR polypeptides.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: December 16, 2014
    Assignee: Amgen Inc.
    Inventors: Chris Saris, Ming-Shi Chang
  • High-affinity fully functional soluble single-domain human CD4, antibodies, and related fusion proteins
    Patent number: 8911728
    Abstract: The invention provides engineered antibody domains (eAds), a polypeptide comprising a single domain CD4, as well as a fusion protein comprising the same. Nucleic acids encoding eAd and/or polypeptide or the fusion protein thereof, as well as compositions or cells comprising the eAd, polypeptide, fusion protein, or nucleic acid also are provided.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: December 16, 2014
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Weizao Chen
  • Stem cell factor inhibitor
    Patent number: 8911729
    Abstract: Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: December 16, 2014
    Assignee: The Regents of The University of Michigan
    Inventors: Nicholas W. Lukacs, Vladislav Dolgachev, Steven L. Kunkel, Cory M. Hogaboam, Sem H. Phan
  • METHODS FOR SUPPRESSING CANCER BY INHIBITION OF TMCC3
    Publication number: 20140363372
    Abstract: A method for treating cancer includes administering to a subject in need thereof an antibody against a transmembrane and coiled-coil domains protein 3 (TMCC3), wherein the antibody binds to an epitope in an extracellular domain of TMCC3. The antibody binds to an epitope in an intercoil domain of TMCC3. A method of diagnosing or assessing a cancer condition includes assessing a level of expression or activity of a transmembrane and coiled-coil domains protein 3 (TMCC3) in a sample, wherein an increase in the level of expression of activity of TMCC3 as compared to a standard indicates the presence of cancer stem cells in the sample.
    Type: Application
    Filed: March 24, 2014
    Publication date: December 11, 2014
    Applicants: DEVELOPMENT CENTER FOR BIOTECHNOLOGY, CHANG GUNG MEMORIAL HOSPITAL, ACADEMIA SINICA
    Inventors: Alice L. Yu, John Yu, Ya-Hui Wang, Chuan-Lung Hsu, Yi-Chang Chen, Ying-Yung Lok
  • NEUREGULIN ANTIBODIES AND USES THEREOF
    Publication number: 20140363438
    Abstract: The invention provides anti-neuregulin1 antibodies and methods of using the antibodies in treating diseases or disorders, such as cancer. In a particular embodiment, the anti-neuregulin1 antibodies bind to both neuregulin1? and neuregulin 1? isoforms.
    Type: Application
    Filed: August 16, 2012
    Publication date: December 11, 2014
    Applicant: Genentech, Inc.
    Inventors: Erica Jackson, Gabriele Schaefer, Yan Wu
  • ANTIBODIES AND THEIR USES FOR DIAGNOSIS AND TREATMENT OF CYTOMEGALOVIRUS INFECTION AND ASSOCIATED DISEASES
    Publication number: 20140363440
    Abstract: Anti CMV antibodies are provided. Thus an antibody of the present invention comprises an antigen recognition domain capable of binding an MHC molecule being complexed with a cytomegalovirus (CMV) pp65 or pp64 peptide, wherein the antibody does not bind said MHC molecule in an absence of said complexed peptide, and wherein the antibody does not bind said peptide in an absence of said MHC molecule. Also provided are methods of using the antibodies.
    Type: Application
    Filed: August 26, 2014
    Publication date: December 11, 2014
    Inventors: Oryan MAKLER, Yoram Reiter
  • ANTI-HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODIES AND METHODS OF USE
    Publication number: 20140363427
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.
    Type: Application
    Filed: June 5, 2014
    Publication date: December 11, 2014
    Inventors: Robert Anthony Williamson, Jehangir Wadia, Gabriel Pascual, Elissa Keogh